7wp8 › Citations

Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine.
<div class='caption-title'>The monomeric STFK is highly immunogenic in rodents and nonhuman primates</div>
<div class='caption-title'>nAb responses elicited by engineered STFK variants in hamsters</div>
Wu Y, Wang S, Zhang Y, Yuan L, Zheng Q, Wei M, Shi Y, Wang Z, Ma J, Wang K, Nie M, Xiao J, Huang Z, Chen P, Guo H, Lan M, Xu J, Hou W, Hong Y, Chen D, Sun H, Xiong H, Zhou M, Liu C, Guo W, Guo H, Gao J, Gan C, Li Z, Zhang H, Wang X, Li S, Cheng T, Zhao Q, Chen Y, Wu T, Zhang T, Zhang J, Cao H, Zhu H, Yuan Q, Guan Y, Xia N
OpenAccess logo Cell Host Microbe 30 1732-1744.e7 (2022)
Cited: 6 times
EuropePMC logo PMID: 36323313

Abstract

SARS-CoV-2 spread in humans results in continuous emergence of new variants, highlighting the need for vaccines with broad-spectrum antigenic coverage. Using inter-lineage chimera and mutation-patch strategies, we engineered a recombinant monomeric spike variant (STFK1628x) that contains key regions and residues across multiple SAR-CoV-2 variants. STFK1628x demonstrated high immunogenicity and mutually complementary antigenicity to its prototypic form (STFK). In hamsters, a bivalent vaccine composed of STFK and STFK1628x elicited high titers of broad-spectrum neutralizing antibodies to 19 circulating SARS-CoV-2 variants, including Omicron sublineages BA.1, BA.1.1, BA.2, BA.2.12.1, BA.2.75, and BA.4/5. Furthermore, this vaccine conferred robust protection against intranasal challenges by either SARS-CoV-2 ancestral strain or immune-evasive Beta and Omicron BA.1. Strikingly, vaccination with the bivalent vaccine in hamsters effectively blocked within-cage virus transmission of ancestral SARS-CoV-2, Beta variant, and Omicron BA.1 to unvaccinated sentinels. Thus, our study provided insight and antigen candidates for the development of next-generation COVID-19 vaccines.

Articles - 7wp8 mentioned but not cited (1)

  1. Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine. Wu Y, Wang S, Zhang Y, Yuan L, Zheng Q, Wei M, Shi Y, Wang Z, Ma J, Wang K, Nie M, Xiao J, Huang Z, Chen P, Guo H, Lan M, Xu J, Hou W, Hong Y, Chen D, Sun H, Xiong H, Zhou M, Liu C, Guo W, Guo H, Gao J, Gan C, Li Z, Zhang H, Wang X, Li S, Cheng T, Zhao Q, Chen Y, Wu T, Zhang T, Zhang J, Cao H, Zhu H, Yuan Q, Guan Y, Xia N. Cell Host Microbe 30 1732-1744.e7 (2022)


Reviews citing this publication (1)

  1. Challenges and developments in universal vaccine design against SARS-CoV-2 variants. Zhao F, Zai X, Zhang Z, Xu J, Chen W. NPJ Vaccines 7 167 (2022)

Articles citing this publication (4)

  1. Broad-spectrum vaccine via combined immunization routes triggers potent immunity to SARS-CoV-2 and its variants. Xing M, Wang Y, Wang X, Liu J, Dai W, Hu G, He F, Zhao Q, Li Y, Sun L, Wang Y, Du S, Dong Z, Pang C, Hu Z, Zhang X, Xu J, Cai Q, Zhou D. J Virol 97 e0072423 (2023)
  2. Cationic crosslinked carbon dots-adjuvanted intranasal vaccine induces protective immunity against Omicron-included SARS-CoV-2 variants. Lei H, Alu A, Yang J, He X, He C, Ren W, Chen Z, Hong W, Chen L, He X, Yang L, Li J, Wang Z, Wang W, Wei Y, Lu S, Lu G, Song X, Wei X. Nat Commun 14 2678 (2023)
  3. Letter Evolving spike mutations in SARS-CoV-2 Omicron variants facilitate evasion from breakthrough infection-acquired antibodies. Chen S, Huang Z, Guo Y, Guo H, Jian L, Xiao J, Yao X, Yu H, Cheng T, Zhang Y, Guan M, Mao R, Zhang J, Xia N, Yuan Q. Cell Discov 9 86 (2023)
  4. SARS-CoV-2 antibodies recognize 23 distinct epitopic sites on the receptor binding domain. Jiang J, Boughter CT, Ahmad J, Natarajan K, Boyd LF, Meier-Schellersheim M, Margulies DH. Commun Biol 6 953 (2023)


Quick links